

Curriculum Vitae

Univ.-Prof. Dr. med. Dan Rujescu

Chair, Department of Psychiatry and Psychotherapy

Medical University of Vienna / AKH Vienna

Waehringer Guertel 18–20, A-1090 Vienna, Austria

Email: dan.rujescu@meduniwien.ac.at | **ORCID:** 0000-0002-1432-313X

Executive Profile for WFSBP Executive Board (Vice-Treasurer)

Senior academic psychiatrist, clinician, and research director with over 20 years of international health governance, departmental administration, and fiscal management experience. Over two decades of continuous, multifaceted service to the **World Federation of Societies of Biological Psychiatry (WFSBP)**, currently serving as Editor-in-Chief of *The World Journal of Biological Psychiatry (WJBP)*, Chair of the Task Force on Genetics, and multi-term World Congress organizer. Substantial background in organizational financial oversight (>€9 million raised and managed in competitive international consortia, hospital management certification) and executive leadership in international scientific societies (former Vice President of CINP; President of the Austrian Society of Psychopharmacology and Biological Psychiatry which is a member of WSBP).

Service to WFSBP

Editor-in-Chief, *The World Journal of Biological Psychiatry (WJBP)* (2019–present).
Direct oversight of editorial policy, peer review workflows, and international indexing.

Field Editor for Molecular Psychiatry, *The World Journal of Biological Psychiatry* (2009–2019)

Chair, WFSBP Task Force on Genetics (2008–present; Secretary 2006–2008)

Member, WFSBP Task Force on Imaging Genetics (2006–present)

Past Member, Committee on International Relations, WFSBP

Past Secretary, Committee on Membership, WFSBP (2006–2008)

World Congress Organisation (WFSBP):

Member, Scientific Programme Committee, 16th World Congress (2023)

Member, Organising Committee, 13th World Congress (2015–2017)

Member, Scientific Programme Committee, 12th World Congress (2014–2015)

Co-Chair, International Scientific Programme Committee, 10th World Congress (2009–2011)

Member, Scientific Programme Committee, 9th World Congress (2007–2009)

Co-Chair, Organising Committee, 7th World Congress (>6,000 participants; 2001)

Institutional Leadership

Professor of Psychiatry and Psychotherapy, Chair of Psychiatry, Medical University of Vienna (2021–present)

W3 Professor of Psychiatry and Psychotherapeutic Medicine, Chair, Department of Psychiatry, Psychotherapy and Psychosomatics, Martin-Luther-Universität Halle-Wittenberg, Germany (2012–2021)

Member of the Faculty Council, Medical Faculty, Martin-Luther-Universität Halle-Wittenberg (2014–2018)

W2 Professor of Psychiatry (Psychiatric Genomics & Clinical Neurobiology), Ludwig-Maximilians-Universität (LMU) Munich (2008–2012)

Managing Consultant, Department of Psychiatry, LMU Munich (2009–2012)

Head, Alzheimer Memorial Center & Geriatric Psychiatry Ward, LMU Munich (2009–2012)

Head, Molecular and Clinical Neurobiology / Genetics Research Centre, LMU Munich (1998–2012)

Financial Stewardship, Budget Oversight & Grant Administration

Total Competitive Third-Party Funds Managed: >€ 9 million (excluding clinical trial industry funds, and grants raised by other members of the department).

Hospital & Health Economics: Formal post-graduate certification from the German Elite Academy (*Deutsche Eliteakademie*, Faculty for Health Economics, 2009).

EU Framework Programme Consortia (PI / WP Lead):

Principal Investigator: *CRESTAR* (FP7 HEALTH, €663,168)

Principal Investigator (Blood Omics & Clinical Trials): *OPTiMiSE* (FP7 HEALTH, €293,741)

- Principal Investigator: *PsychDPC* (FP7-PEOPLE-IAPP, €194,452)
- Principal Investigator: *SGENE* (FP6 STREP, €391,280)
- Consortium Partner / PI: *EU-GEI* (FP7), *PERADES* (JPND), *EADB* (JPND), *EDAR* (FP6)
- **US National Institutes of Health (NIH R01):**
 - Principal Investigator: 1R01MH082182-01A1 (*Suicidal behavior in mood disorders*, €181,000)
 - Principal Investigator: 1R01MH092380-01A1 (*GENUS Consortium*)
- **Wellcome Trust Initiatives:**
 - Co-Applicant: *Wellcome Trust Case-Control Consortium 2 (WTCCC2)* (€691,497)
 - Collaborator: *WTCCC3* (Anorexia Nervosa)
- **National Research Programs (Germany & Austria):**
 - Principal Investigator: BMBF-NGFNplus *MooDS* (€927,418); BMBF *m4 Excellence Cluster* (€93,445); BMBF Individualised Medicine *hiPS Models* (€310,696); BMG Suicide Prevention Projects (€212,027); Bavarian Research Foundation (€415,000) etc.

International Psychiatric Society Governance

- **Member of the Executive Committee, Past Vice President**, Collegium Internationale Neuro-Psychopharmacologicum (CINP)
- **Chair, Ethics Committee**, CINP
- **President**, Austrian Society of Psychopharmacology and Biological Psychiatry (ÖGPB) (2022–present)
- **Past Board Member**, International Society of Psychiatric Genetics (ISPG)
- **Co-Chair & Secretary**, Section on Suicidology, European Psychiatric Association (EPA)
- **Chair**, German Academy for Suicide Prevention (DASP) (2017–present)

Education & Medical Qualifications

- **2009:** Certification in Hospital Management & Health Economics, German Elite Academy

- **2004:** Habilitation & *Venia Legendi* in Psychiatry and Psychotherapy, LMU Munich ("*Molecular genetics of suicidal behaviour*")
- **2003:** Board Certification, Specialist in Psychiatry and Psychotherapy (Subspecialty: Cognitive Behaviour Therapy)
- **1995:** Full Medical Licence (*Approbation*), Germany
- **1991–1993:** Medical Doctorate (Dr. med.), Universities of Essen and Heidelberg
- **1986–1993:** Medical School, University of Essen (Clinical placements: San Francisco, Brisbane, Cape Town)

Scientific Indices:

Journal Articles	>650
Citations	>103,000 (Google Scholar)
h-Index	139 (Google Scholar)
Global Recognition	Clarivate Analytics " Highly Cited Researcher "
International Consortia	Co-founder/Steering: Psychiatric Genomics Consortium (PGC), SGENE, OPTiMiSE, CRESTAR, etc.; Member: GERAD, EADB, NAKO, etc.

Selected Publications

1. **Stefansson H*, Rujescu D*, Cichon S***, et al. Large recurrent microdeletions associated with schizophrenia. *Nature*. 2008;455(7210):232–236.
2. **Stefansson H**, Ophoff RA, ..., **Rujescu D**, et al. Common variants conferring risk of schizophrenia. *Nature*. 2009;460(7256):744–747.
3. **Rujescu D**, et al. Disruption of the neurexin 1 gene is associated with schizophrenia. *Hum Mol Genet*. 2009;18(5):988–996.
4. **Jonsson T**, Stefansson H, ..., **Rujescu D**, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med*. 2013;368(2):107–116.
5. **Schizophrenia Working Group of the PGC (Rujescu D)**. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421–427.

6. **Yoon KJ, ..., Rujescu D, et al.** Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity. *Cell Stem Cell*. 2014;15(1):79–91.
7. **Sekar A, ..., Rujescu D, et al.** Schizophrenia risk from complex variation of complement component 4. *Nature*. 2016;530(7589):177–183.
8. **Marshall CR, ..., Rujescu D, et al.** Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet*. 2017;49(1):27–35.
9. **Kamitaki N, ..., Rujescu D, et al.** Complement genes contribute sex-biased vulnerability in diverse disorders. *Nature*. 2020;582(7813):577–581.
10. **Trubetskoy V, ..., Rujescu D, et al.** Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*. 2022;604(7906):502–508.